For help on how to get the results you want, see our search tips.
1550 results
Medicine
European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Nucala (updated)
Mepolizumab, Asthma
Date of authorisation: 01/12/2015, Revision: 14, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Velcade (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 26/04/2004, Revision: 44, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Flixabi (updated)
infliximab, Spondylitis, Ankylosing, Arthritis, Rheumatoid, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Psoriasis
Date of authorisation: 26/05/2016,
, 
, Revision: 16, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Qutenza (updated)
capsaicin, Neuralgia
Date of authorisation: 15/05/2009, Revision: 15, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Karvezide (updated)
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 16/10/1998, Revision: 40, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Topotecan Hospira (updated)
topotecan, Uterine Cervical Neoplasms, Small Cell Lung Carcinoma
Date of authorisation: 09/06/2010, Revision: 16, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Herzuma (updated)
trastuzumab, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 08/02/2018,, , Revision: 11, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Stelara (updated)
Ustekinumab, Psoriasis, Arthritis, Psoriatic, Crohn Disease
Date of authorisation: 15/01/2009, Revision: 34, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Orfadin (updated)
nitisinone, Tyrosinemias
Date of authorisation: 20/02/2005, Revision: 20, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Epidyolex (updated)
Cannabidiol, Lennox Gastaut Syndrome, Epilepsies, Myoclonic
Date of authorisation: 19/09/2019,
, Revision: 5, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Repatha (updated)
Evolocumab, Dyslipidemias, Hypercholesterolemia
Date of authorisation: 17/07/2015, Revision: 16, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Pioglitazone Teva (updated)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012,
, Revision: 11, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Braftovi (updated)
Encorafenib, Melanoma, Colorectal Neoplasms
Date of authorisation: 19/09/2018,, Revision: 5, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Gencebok (updated)
Caffeine citrate, Apnea
Date of authorisation: 19/08/2020, Revision: 2, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Aubagio (updated)
Teriflunomide, Multiple Sclerosis
Date of authorisation: 26/08/2013, Revision: 17, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Eylea (updated)
aflibercept, Wet Macular Degeneration, Macular Edema, Diabetes Complications
Date of authorisation: 21/11/2012, Revision: 20, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Ondexxya (updated)
andexanet alfa, Drug-Related Side Effects and Adverse Reactions
Date of authorisation: 26/04/2019,, 
, Revision: 8, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Karvea (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 40, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Glivec (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gastrointestinal Stromal Tumors, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 07/11/2001,, Revision: 40, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): CoAprovel (updated)
irbesartan, hydrochlorothiazide, Hypertension
Date of authorisation: 14/10/1998, Revision: 41, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Byetta (updated)
exenatide, Diabetes Mellitus, Type 2
Date of authorisation: 20/11/2006, Revision: 24, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Praluent (updated)
Alirocumab, Dyslipidemias
Date of authorisation: 23/09/2015,, Revision: 16, Authorised, Last updated: 01/03/2021
-
List item
Human medicine European public assessment report (EPAR): Bydureon (updated)
exenatide, Diabetes Mellitus, Type 2
Date of authorisation: 17/06/2011, Revision: 21, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Aprovel (updated)
irbesartan, Hypertension
Date of authorisation: 26/08/1997, Revision: 42, Authorised, Last updated: 01/03/2021 -
List item
Human medicine European public assessment report (EPAR): Tadalafil Lilly (updated)
tadalafil, Erectile Dysfunction
Date of authorisation: 22/03/2017, Revision: 3, Authorised, Last updated: 01/03/2021